Syndrome of inappropriate antidiuretic hormone secretion following irinotecan-cisplatin administration as a treatment for recurrent ovarian clear cell carcinoma.
10.5468/ogs.2017.60.1.115
- Author:
Do Youn KWON
1
;
Gwan Hee HAN
;
Roshani ULAK
;
Kyung Do KI
;
Jong Min LEE
;
Seon Kyung LEE
Author Information
1. Department of Obstetrics and Gynecology, Kyung Hee University Hospital at Gangdong, Seoul, Korea. diners99@naver.com
- Publication Type:Case Report
- Keywords:
Cisplatin;
Inappropriate ADH syndrome;
Irinotecan;
Ovarian cancer, clear cell
- MeSH:
Central Nervous System Diseases;
Chemotherapy, Adjuvant;
Cisplatin;
Drug Therapy;
Drug Therapy, Combination;
Early Diagnosis;
Endocrine System Diseases;
Female;
Hematologic Tests;
Humans;
Hyponatremia;
Inappropriate ADH Syndrome;
Middle Aged;
Paraneoplastic Syndromes;
Sodium
- From:Obstetrics & Gynecology Science
2017;60(1):115-117
- CountryRepublic of Korea
- Language:English
-
Abstract:
Syndrome of inappropriate antidiuretic hormone secretion (SIADH) has various causes including central nervous system disorders, pulmonary and endocrine diseases, paraneoplastic syndromes, and use of certain drugs. SIADH induced by chemotherapy with irinotecan-cisplatin is not a common complication. Here, we review a case of SIADH after treatment with irinotecan-cisplatin. A 45-year-old woman received adjuvant chemotherapy (paclitaxel-carboplatin) for ovarian clear cell carcinoma, but the cancer recurred within 9 months of chemotherapy. Subsequently, a second line of combination chemotherapy containing irinotecan-cisplatin was initiated. However, 5 days after chemotherapy administration, her general condition began to deteriorate; her hematological tests revealed hyponatremia. Therefore, it is imperative to consider the possibility of SIADH in patients being treated with irinotecan-cisplatin–based chemotherapy. Proper monitoring of serum sodium levels and assessment of clinical symptoms should be performed in such patients for early diagnosis and prompt management.
